WOOF vs CHWY vs FRPT vs TRUP vs IDXX

For growth investors, Freshpet, Inc.

(FRPT) is the stronger pick with 13. 0% revenue growth year-over-year, versus -2. 5% for Petco Health and Wellness Company, Inc. (WOOF). Freshpet, Inc. (FRPT) offers the better valuation at 21. 2x trailing P/E (41. 1x forward), making it the more compelling value choice. Analysts rate Chewy, Inc. (CHWY) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Freshpet, Inc.

(FRPT) is the cheapest at 21. 2x versus Petco Health and Wellness Company, Inc. at 86. 8x. On forward P/E, Petco Health and Wellness Company, Inc. is actually cheaper at 18. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -88. 5% for Petco Health and Wellness Company, Inc. (WOOF). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus WOOF's -90. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Chewy, Inc.

(CHWY) is the lower-risk stock at 0. 70β versus IDEXX Laboratories, Inc. 's 1. 35β — meaning IDXX is approximately 91% more volatile than CHWY relative to the S&P 500. On balance sheet safety, Trupanion, Inc. (TRUP) carries a lower debt/equity ratio of 29% versus 192% for Chewy, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Freshpet, Inc.

(FRPT) is pulling ahead at 13. 0% versus -2. 5% for Petco Health and Wellness Company, Inc. (WOOF). On earnings-per-share growth, the picture is similar: Chewy, Inc. grew EPS 893. 4% year-over-year, compared to 22. 6% for IDEXX Laboratories, Inc.. Over a 3-year CAGR, FRPT leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus 0. 2% for Petco Health and Wellness Company, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 0. 9% for CHWY. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Petco Health and Wellness Company, Inc.

(WOOF) trades at 18. 8x forward P/E versus 49. 5x for Trupanion, Inc. — 30. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CHWY: 76. 3% to $41. 71.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Freshpet, Inc.

(FRPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), +517. 3% 10Y return). Both have compounded well over 10 years (FRPT: +517. 3%, WOOF: -90. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WOOF (Consumer Cyclical) and CHWY (Consumer Cyclical) and FRPT (Consumer Defensive) and TRUP (Financial Services) and IDXX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.